bluebird bio Inc (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, …
bluebird bio Inc (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for …
Leerink and Wedbush analysts highlight potential catalysts for Intercept Pharmaceuticals Inc (NASDAQ:ICPT) and bluebird bio Inc (NASDAQ:BLUE). One analyst believes that better than expected briefing …
In a research report released Friday, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on shares of bluebird bio Inc (NASDAQ:BLUE) with a …
Biotech analysts weighed in on specialty drug maker Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and biotechnology firm bluebird bio Inc (NASDAQ:BLUE). The analysts are cautious on …
While the biotech tape remains a challenging one, Maxim analysts remain positive on drug maker Keryx Biopharmaceuticals (NASDAQ:KERX) and gene-therapy-product maker bluebird bio Inc (NASDAQ:BLUE). Below …
Roth Capital’s healthcare analysts weigh in on biotech stocks Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) and bluebird bio Inc (NASDAQ:BLUE). While Catalyst pharma received a “Refusal to File” letter from …
Analyst Joshua Schimmer of Piper Jaffray weighed in on bluebird bio Inc (NASDAQ:BLUE) and Regenxbio Inc (NASDAQ:RGNX) today to kick off the year. The analyst …
